Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models

Abstract

Fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) signaling plays essential roles in bone development and diseases. Missense mutations in FGFs and FGFRs in humans can cause various congenital bone diseases, including chondrodysplasia syndromes, craniosynostosis syndromes and syndromes with dysregulated phosphate metabolism. FGF/FGFR signaling is also an important pathway involved in the maintenance of adult bone homeostasis. Multiple kinds of mouse models, mimicking human skeleton diseases caused by missense mutations in FGFs and FGFRs, have been established by knock-in/out and transgenic technologies. These genetically modified mice provide good models for studying the role of FGF/FGFR signaling in skeleton development and homeostasis. In this review, we summarize the mouse models of FGF signaling-related skeleton diseases and recent progresses regarding the molecular mechanisms, underlying the role of FGFs/FGFRs in the regulation of bone development and homeostasis. This review also provides a perspective view on future works to explore the roles of FGF signaling in skeletal development and homeostasis.

Bone disease: Mouse models offer new drug leads

Mouse models are revealing new insights into the roles of fibroblast growth factor (FGF) in human bone development and skeletal diseases. In a review article, Lin Chen and colleagues from the Third Military Medical University in Chongqing, China, highlight the many essential roles that FGFs, a family of growth factors, and their receptors play in the formation of a healthy skeleton. Mutations in FGF-associated genes can cause a range of congenital bone disorders. The authors discuss the ways in which scientists are genetically engineering mice to harbor mutations in a range of genes coding for FGFs and their receptors. These animal models are offering a window into the molecular mechanisms that underlie genetic skeletal diseases and providing attractive drug targets for treating many bone-related disorders.

References

[1] Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell, 2002, 2: 389-406

[2] Su N, Du X, Chen L. FGF signaling: its role in bone development and human skeleton diseases. Front Biosci, 2008, 13: 2842-2865

[3] Chen L, Deng CX. Roles of FGF signaling in skeletal development and human genetic diseases. Front Biosci, 2005, 10: 1961-1976

[4] Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res, 1993, 60: 1-41

[5] Ornitz DM, Xu J, Colvin JS et al Receptor specificity of the fibroblast growth factor family. J Biol Chem, 1996, 271: 15292-15297

[6] Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocrine Relat Cancer, 2000, 7: 165-197

[7] Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev, 2005, 16: 205-213

[8] Yamaguchi TP, Conlon RA, Rossant J. Expression of the fibroblast growth factor receptor FGFR-1/flg during gastrulation and segmentation in the mouse embryo. Dev Biol, 1992, 152: 75-88

[9] Peters KG, Werner S, Chen G, Williams LT. Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development, 1992, 114: 233-243

[10] Verheyden JM, Lewandoski M, Deng C, Harfe BD, Sun X. Conditional inactivation of Fgfr1 in mouse defines its role in limb bud establishment, outgrowth and digit patterning. Development, 2005, 132: 4235-4245

[11] Lazarus JE, Hegde A, Andrade AC, Nilsson O, Baron J. Fibroblast growth factor expression in the postnatal growth plate. Bone, 2007, 40: 577-586

[12] Szebenyi G, Savage MP, Olwin BB, Fallon JF. Changes in the expression of fibroblast growth factor receptors mark distinct stages of chondrogenesis in vitro and during chick limb skeletal patterning. Dev Dyn, 1995, 204: 446-456

[13] Iseki S, Wilkie AO, Morriss-Kay GM. Fgfr1 and Fgfr2 have distinct differentiation- and proliferation-related roles in the developing mouse skull vault. Development, 1999, 126: 5611-5620

[14] Xiao L, Naganawa T, Obugunde E et al Stat1 controls postnatal bone formation by regulating fibroblast growth factor signaling in osteoblasts. J Biol Chem, 2004, 279: 27743-27752

[15] Jacob AL, Smith C, Partanen J, Ornitz DM. Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. Dev Biol, 2006, 296: 315-328

[16] Kyono A, Avishai N, Ouyang Z, Landreth GE, Murakami S. FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation. J Bone Miner Metab, 2012, 30: 19-30

[17] Deng CX, Wynshaw-Boris A, Shen MM, Daugherty C, Ornitz DM, Leder P. Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev, 1994, 8: 3045-3057

[18] Yamaguchi TP, Harpal K, Henkemeyer M, Rossant J. fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev, 1994, 8: 3032-3044

[19] Partanen J, Schwartz L, Rossant J. Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for Fgfr1 in anteroposterior patterning of mouse embryos. Genes Dev, 1998, 12: 2332-2344

[20] Xu X, Li C, Takahashi K, Slavkin HC, Shum L, Deng CX. Murine fibroblast growth factor receptor 1alpha isoforms mediate node regression and are essential for posterior mesoderm development. Dev Biol, 1999, 208: 293-306

[21] Deng C, Bedford M, Li C et al Fibroblast growth factor receptor-1 (FGFR-1) is essential for normal neural tube and limb development. Dev Biol, 1997, 185: 42-54

[22] Perantoni AO, Timofeeva O, Naillat F et al Inactivation of FGF8 in early mesoderm reveals an essential role in kidney development. Development, 2005, 132: 3859-3871

[23] Harfe BD, Scherz PJ, Nissim S, Tian H, McMahon AP, Tabin CJ. Evidence for an expansion-based temporal Shh gradient in specifying vertebrate digit identities. Cell, 2004, 118: 517-528

[24] Li C, Xu X, Nelson DK, Williams T, Kuehn MR, Deng CX. FGFR1 function at the earliest stages of mouse limb development plays an indispensable role in subsequent autopod morphogenesis. Development, 2005, 132: 4755-4764

[25] Hoch RV, Soriano P. Context-specific requirements for Fgfr1 signaling through Frs2 and Frs3 during mouse development. Development, 2006, 133: 663-673

[26] White KE, Cabral JM, Davis SI et al Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet, 2005, 76: 361-367

[27] Roscioli T, Flanagan S, Kumar P et al Clinical findings in a patient with FGFR1 P252R mutation and comparison with the literature. Am J Med Genet, 2000, 93: 22-28

[28] Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX. A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet, 2000, 9: 2001-2008

[29] Lu X, Su N, Yang J et al Fibroblast growth factor receptor 1 regulates the differentiation and activation of osteoclasts through Erk1/2 pathway. Biochem Biophys Res Commun, 2009, 390: 494-499

[30] Yu X, White KE. Fibroblast growth factor 23 and its receptors. Ther Apher Dial, 2005, 9: 308-312

[31] Quarles LD. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol, 2012, 8: 276-286

[32] Wohrle S, Bonny O, Beluch N et al FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res, 2011, 26: 2486-2497

[33] Peng H, Myers J, Fang X et al Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C. J Neurochem, 2002, 81: 506-524

[34] Delezoide AL, Benoist-Lasselin C, Legeai-Mallet L et al Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification. Mech Dev, 1998, 77: 19-30

[35] Orr-Urtreger A, Bedford MT, Burakova T et al Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol, 1993, 158: 475-486

[36] Yu K, Xu J, Liu Z et al Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development, 2003, 130: 3063-3074

[37] Rice DP, Rice R, Thesleff I. Fgfr mRNA isoforms in craniofacial bone development. Bone, 2003, 33: 14-27

[38] Rice DP, Aberg T, Chan Y et al Integration of FGF and TWIST in calvarial bone and suture development. Development, 2000, 127: 1845-1855

[39] Yin L, Du X, Li C et al A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis. Bone, 2008, 42: 631-643

[40] Wilkie AO. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev, 2005, 16: 187-203

[41] Britto JA, Chan JC, Evans RD, Hayward RD, Thorogood P, Jones BM. Fibroblast growth factor receptors are expressed in craniosynostotic sutures. Plast Reconstr Surg, 1998, 101: 540-543

[42] Britto JA, Evans RD, Hayward RD, Jones BM. From genotype to phenotype: the differential expression of FGF, FGFR, and TGFbeta genes characterizes human cranioskeletal development and reflects clinical presentation in FGFR syndromes. Plast Reconstr Surg, 2001, 108: 2026-2039; discussion 2040–2026

[43] Arman E, Haffner-Krausz R, Chen Y, Heath JK, Lonai P. Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc Natl Acad Sci USA, 1998, 95: 5082-5087

[44] Xu X, Weinstein M, Li C et al Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. Development, 1998, 125: 753-765

[45] Li X, Chen Y, Scheele S et al Fibroblast growth factor signaling and basement membrane assembly are connected during epithelial morphogenesis of the embryoid body. J Cell Biol, 2001, 153: 811-822

[46] Marie PJ, Coffin JD, Hurley MM. FGF and FGFR signaling in chondrodysplasias and craniosynostosis. J Cell Biochem, 2005, 96: 888-896

[47] Cunningham ML, Seto ML, Ratisoontorn C, Heike CL, Hing AV. Syndromic craniosynostosis: from history to hydrogen bonds. Orthod Craniofac Res, 2007, 10: 67-81

[48] Wang Y, Xiao R, Yang F et al Abnormalities in cartilage and bone development in the Apert syndrome FGFR2 ^(+/S252W) mouse. Development, 2005, 132: 3537-3548

[49] Wang Y, Sun M, Uhlhorn VL et al Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2 ^(+P253R) mice. BMC Dev Biol, 2010, 10: 22

[50] Kreiborg S, Aduss H, Cohen MM Jr. Cephalometric study of the Apert syndrome in adolescence and adulthood. J Craniofac Genet Dev Biol, 1999, 19: 1-11

[51] Chen L, Li D, Li C, Engel A, Deng CX. A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis. Bone, 2003, 33: 169-178

[52] Wang Y, Zhou X, Oberoi K et al p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare–Stevenson mice. J Clin Invest, 2012, 122: 2153-2164

[53] Eswarakumar VP, Ozcan F, Lew ED et al Attenuation of signaling pathways stimulated by pathologically activated FGF-receptor 2 mutants prevents craniosynostosis. Proc Natl Acad Sci USA, 2006, 103: 18603-18608

[54] Eswarakumar VP, Monsonego-Ornan E, Pines M, Antonopoulou I, Morriss-Kay GM, Lonai P. The IIIc alternative of Fgfr2 is a positive regulator of bone formation. Development, 2002, 129: 3783-3793

[55] Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P. A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci USA, 2004, 101: 12555-12560

[56] Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. RNA interference and inhibition of MEK–ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet, 2007, 39: 1145-1150

[57] Coumoul X, Shukla V, Li C, Wang RH, Deng CX. Conditional knockdown of Fgfr2 in mice using Cre-LoxP induced RNA interference. Nucleic Acids Res, 2005, 33: e102

[58] Peters K, Ornitz D, Werner S, Williams L. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev Biol, 1993, 155: 423-430

[59] Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet, 1996, 12: 390-397

[60] Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev, 2002, 16: 1446-1465

[61] Rousseau F, Bonaventure J, Legeai-Mallet L et al Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature, 1994, 371: 252-254

[62] Bellus GA, Hefferon TW, Ortiz de Luna RI et al Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet, 1995, 56: 368-373

[63] Passos-Bueno MR, Wilcox WR, Jabs EW, Sertie AL, Alonso LG, Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat, 1999, 14: 115-125

[64] Rousseau F, el Ghouzzi V, Delezoide AL, Legeai-Mallet L, Le Merrer M, Munnich A, Bonaventure J. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). Hum Mol Genet, 1996, 5: 509-512

[65] Bellus GA, Bamshad MJ, Przylepa KA et al Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet, 1999, 85: 53-65

[66] Tavormina PL, Bellus GA, Webster MK et al A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet, 1999, 64: 722-731

[67] Wang JM, Du XL, Li CL et al Gly374Arg mutation in Fgfr3 causes achondroplasia in mice. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2004, 21: 537-541

[68] Wang Y, Spatz MK, Kannan K et al A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci USA, 1999, 96: 4455-4460

[69] Naski MC, Colvin JS, Coffin JD, Ornitz DM. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development, 1998, 125: 4977-4988

[70] Chen L, Adar R, Yang X et al Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J Clin Invest, 1999, 104: 1517-1525

[71] Iwata T, Chen L, Li C et al A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum Mol Genet, 2000, 9: 1603-1613

[72] Chen L, Li C, Qiao W, Xu X, Deng C. A Ser(365)-->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum Mol Genet, 2001, 10: 457-465

[73] Li C, Chen L, Iwata T, Kitagawa M, Fu XY, Deng CX. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet, 1999, 8: 35-44

[74] Su WC, Kitagawa M, Xue N et al Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature, 1997, 386: 288-292

[75] Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev, 1999, 13: 1361-1366

[76] Murakami S, Balmes G, McKinney S, Zhang Z, Givol D, de Crombrugghe B. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev, 2004, 18: 290-305

[77] Minina E, Kreschel C, Naski MC, Ornitz DM, Vortkamp A. Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell, 2002, 3: 439-449

[78] Dailey L, Laplantine E, Priore R, Basilico C. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. J Cell Biol, 2003, 161: 1053-1066

[79] Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell, 1996, 84: 911-921

[80] Naski MC, Ornitz DM. FGF signaling in skeletal development. Front Biosci, 1998, 3: 781-794

[81] Koike M, Yamanaka Y, Inoue M, Tanaka H, Nishimura R, Seino Y. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK. J Bone Miner Res, 2003, 18: 2043-2051

[82] Matsushita T, Wilcox WR, Chan YY et al FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum Mol Genet, 2009, 18: 227-240

[83] Su N, Sun Q, Li C et al Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis. Hum Mol Genet, 2010, 19: 1199-1210

[84] Marie PJ, Miraoui H, Severe N. FGF/FGFR signaling in bone formation: progress and perspectives. Growth Factors, 2012, 30: 117-123

[85] Valverde-Franco G, Liu H, Davidson D et al Defective bone mineralization and osteopenia in young adult FGFR3 ^−/− mice. Hum Mol Genet, 2004, 13: 271-284

[86] Yasoda A, Komatsu Y, Chusho H et al Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med, 2004, 10: 80-86

[87] Ozasa A, Komatsu Y, Yasoda A et al Complementary antagonistic actions between C-type natriuretic peptide and the MAPK pathway through FGFR-3 in ATDC5 cells. Bone, 2005, 36: 1056-1064

[88] Ogawa T, Yamagiwa H, Hayami T et al Human PTH (1–34) induces longitudinal bone growth in rats. J Bone Miner Metab, 2002, 20: 83-90

[89] Ueda K, Yamanaka Y, Harada D, Yamagami E, Tanaka H, Seino Y. PTH has the potential to rescue disturbed bone growth in achondroplasia. Bone, 2007, 41: 13-18

[90] Xie Y, Su N, Jin M et al Intermittent PTH (1–34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia. Hum Mol Genet, 2012, 21: 3941-3955

[91] Jin M, Yu Y, Qi H et al A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Hum Mol Genet, 2012, 21: 5443-5455

[92] Cool S, Jackson R, Pincus P, Dickinson I, Nurcombe V. Fibroblast growth factor receptor 4 (FGFR4) expression in newborn murine calvaria and primary osteoblast cultures. Int J Dev Biol, 2002, 46: 519-523

[93] Weinstein M, Xu X, Ohyama K, Deng CX. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development, 1998, 125: 3615-3623

[94] Fei Y, Hurley MM. Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation. J Cell Physiol, 2012, 227: 3539-3545

[95] Montero A, Okada Y, Tomita M et al Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest, 2000, 105: 1085-1093

[96] Fallon JF, Lopez A, Ros MA, Savage MP, Olwin BB, Simandl BK. FGF-2: apical ectodermal ridge growth signal for chick limb development. Science, 1994, 264: 104-107

[97] Coffin JD, Florkiewicz RZ, Neumann J et al Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol Biol Cell, 1995, 6: 1861-1873

[98] Sahni M, Raz R, Coffin JD, Levy D, Basilico C. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development, 2001, 128: 2119-2129

[99] Ortega S, Ittmann M, Tsang SH, Ehrlich M, Basilico C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci USA, 1998, 95: 5672-5677

[100] Zhou M, Sutliff RL, Paul RJ et al Fibroblast growth factor 2 control of vascular tone. Nat Med, 1998, 4: 201-207

[101] Xiao L, Sobue T, Esliger A et al Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. Bone, 2010, 47: 360-370

[102] Sobue T, Naganawa T, Xiao L et al Over-expression of fibroblast growth factor-2 causes defective bone mineralization and osteopenia in transgenic mice. J Cell Biochem, 2005, 95: 83-94

[103] Sabbieti MG, Agas D, Xiao L et al Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol, 2009, 219: 143-151

[104] Naganawa T, Xiao L, Abogunde E et al In vivo and in vitro comparison of the effects of FGF-2 null and haplo-insufficiency on bone formation in mice. Biochem Biophys Res Commun, 2006, 339: 490-498

[105] Okada Y, Montero A, Zhang X et al Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. J Biol Chem, 2003, 278: 21258-21266

[106] Fei Y, Xiao L, Hurley MM. The impaired bone anabolic effect of PTH in the absence of endogenous FGF2 is partially due to reduced ATF4 expression. Biochem Biophys Res Commun, 2011, 412: 160-164

[107] Sabbieti MG, Agas D, Marchetti L et al Signaling pathways implicated in PGF2alpha effects on Fgf2 ^+/+ and Fgf2 ^−/− osteoblasts. J Cell Physiol, 2010, 224: 465-474

[108] Xiao L, Liu P, Li X et al Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice. J Biol Chem, 2009, 284: 3170-3182

[109] Xiao L, Naganawa T, Lorenzo J, Carpenter TO, Coffin JD, Hurley MM. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. J Biol Chem, 2010, 285: 2834-2846

[110] Xiao L, Esliger A, Hurley MM. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J Bone Miner Res, 2013, 28: 35-45

[111] Moon AM, Boulet AM, Capecchi MR. Normal limb development in conditional mutants of Fgf4. Development, 2000, 127: 989-996

[112] Lewandoski M, Sun X, Martin GR. Fgf8 signalling from the AER is essential for normal limb development. Nat Genet, 2000, 26: 460-463

[113] Feldman B, Poueymirou W, Papaioannou VE, DeChiara TM, Goldfarb M. Requirement of FGF-4 for postimplantation mouse development. Science, 1995, 267: 246-249

[114] Mathijssen IM, van Leeuwen H, Vermeij-Keers C, Vaandrager JM. FGF-4 or FGF-2 administration induces apoptosis, collagen type I expression, and mineralization in the developing coronal suture. J Craniofac Surg, 2001, 12: 399-400

[115] Kim HJ, Rice DP, Kettunen PJ, Thesleff I. FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development, 1998, 125: 1241-1251

[116] Kuroda S, Kasugai S, Oida S, Iimura T, Ohya K, Ohyama T. Anabolic effect of aminoterminally truncated fibroblast growth factor 4 (FGF4) on bone. Bone, 1999, 25: 431-437

[117] Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ, Lim DS. Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K–Akt and ERK1/2 signaling pathways. Stem Cells Dev, 2008, 17: 725-736

[118] Farre J, Roura S, Prat-Vidal C et al FGF-4 increases in vitro expansion rate of human adult bone marrow-derived mesenchymal stem cells. Growth Factors, 2007, 25: 71-76

[119] Kim HJ, Kim JH, Bae SC, Choi JY, Ryoo HM. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem, 2003, 278: 319-326

[120] Heikinheimo M, Lawshe A, Shackleford GM, Wilson DB, MacArthur CA. Fgf-8 expression in the post-gastrulation mouse suggests roles in the development of the face, limbs and central nervous system. Mech Dev, 1994, 48: 129-138

[121] Mahmood R, Bresnick J, Hornbruch A et al A role for FGF-8 in the initiation and maintenance of vertebrate limb bud outgrowth. Curr Biol, 1995, 5: 797-806

[122] Crossley PH, Minowada G, MacArthur CA, Martin GR. Roles for FGF8 in the induction, initiation, and maintenance of chick limb development. Cell, 1996, 84: 127-136

[123] Sun X, Meyers EN, Lewandoski M, Martin GR. Targeted disruption of Fgf8 causes failure of cell migration in the gastrulating mouse embryo. Genes Dev, 1999, 13: 1834-1846

[124] Meyers EN, Lewandoski M, Martin GR. An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat Genet, 1998, 18: 136-141

[125] Moon AM, Capecchi MR. Fgf8 is required for outgrowth and patterning of the limbs. Nat Genet, 2000, 26: 455-459

[126] Boulet AM, Moon AM, Arenkiel BR, Capecchi MR. The roles of Fgf4 and Fgf8 in limb bud initiation and outgrowth. Dev Biol, 2004, 273: 361-372

[127] Xu J, Lawshe A, MacArthur CA, Ornitz DM. Genomic structure, mapping, activity and expression of fibroblast growth factor 17. Mech Dev, 1999, 83: 165-178

[128] Valta MP, Hentunen T, Qu Q et al Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology, 2006, 147: 2171-2182

[129] Omoteyama K, Takagi M. FGF8 regulates myogenesis and induces Runx2 expression and osteoblast differentiation in cultured cells. J Cell Biochem, 2009, 106: 546-552

[130] Lin JM, Callon KE, Lin JS et al Actions of fibroblast growth factor-8 in bone cells in vitro. Am J Physiol Endocrinol Metab, 2009, 297: E142-E150

[131] Uchii M, Tamura T, Suda T, Kakuni M, Tanaka A, Miki I. Role of fibroblast growth factor 8 (FGF8) in animal models of osteoarthritis. Arthritis Res Ther, 2008, 10: R90

[132] Hecht D, Zimmerman N, Bedford M, Avivi A, Yayon A. Identification of fibroblast growth factor 9 (FGF9) as a high affinity, heparin dependent ligand for FGF receptors 3 and 2 but not for FGF receptors 1 and 4. Growth Factors, 1995, 12: 223-233

[133] Garofalo S, Kliger-Spatz M, Cooke JL et al Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice. J Bone Miner Res, 1999, 14: 1909-1915

[134] Colvin JS, Feldman B, Nadeau JH, Goldfarb M, Ornitz DM. Genomic organization and embryonic expression of the mouse fibroblast growth factor 9 gene. Dev Dyn, 1999, 216: 72-88

[135] Hung IH, Yu K, Lavine KJ, Ornitz DM. FGF9 regulates early hypertrophic chondrocyte differentiation and skeletal vascularization in the developing stylopod. Dev Biol, 2007, 307: 300-313

[136] Colvin JS, White AC, Pratt SJ, Ornitz DM. Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. Development, 2001, 128: 2095-2106

[137] Colvin JS, Green RP, Schmahl J, Capel B, Ornitz DM. Male-to-female sex reversal in mice lacking fibroblast growth factor 9. Cell, 2001, 104: 875-889

[138] Fakhry A, Ratisoontorn C, Vedhachalam C et al Effects of FGF-2/-9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential. Bone, 2005, 36: 254-266

[139] Govindarajan V, Overbeek PA. FGF9 can induce endochondral ossification in cranial mesenchyme. BMC Dev Biol, 2006, 6: 7

[140] Harada M, Murakami H, Okawa A et al FGF9 monomer-dimer equilibrium regulates extracellular matrix affinity and tissue diffusion. Nat Genet, 2009, 41: 289-298

[141] Wu XL, Gu MM, Huang L et al Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene. Am J Hum Genet, 2009, 85: 53-63

[142] Lin Y, Liu G, Wang F. Generation of an Fgf9 conditional null allele. Genesis, 2006, 44: 150-154

[143] Martin GR. The roles of FGFs in the early development of vertebrate limbs. Genes Dev, 1998, 12: 1571-1586

[144] Ohuchi H, Nakagawa T, Yamamoto A et al The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor. Development, 1997, 124: 2235-2244

[145] Min H, Danilenko DM, Scully SA et al Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev, 1998, 12: 3156-3161

[146] Sekine K, Ohuchi H, Fujiwara M et al Fgf10 is essential for limb and lung formation. Nat Genet, 1999, 21: 138-141

[147] Liu Z, Xu J, Colvin JS, Ornitz DM. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev, 2002, 16: 859-869

[148] Ohbayashi N, Shibayama M, Kurotaki Y et al FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev, 2002, 16: 870-879

[149] Mukherjee A, Dong SS, Clemens T, Alvarez J, Serra R. Co-ordination of TGF-beta and FGF signaling pathways in bone organ cultures. Mech Dev, 2005, 122: 557-571

[150] Shimoaka T, Ogasawara T, Yonamine A et al Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. J Biol Chem, 2002, 277: 7493-7500

[151] Reinhold MI, Abe M, Kapadia RM, Liao Z, Naski MC. FGF18 represses noggin expression and is induced by calcineurin. J Biol Chem, 2004, 279: 38209-38219

[152] Liu Z, Lavine KJ, Hung IH, Ornitz DM. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. Dev Biol, 2007, 302: 80-91

[153] Goetz R, Beenken A, Ibrahimi OA et al Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol, 2007, 27: 3417-3428

[154] Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn, 2008, 237: 18-27

[155] Potthoff MJ, Inagaki T, Satapati S et al FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA, 2009, 106: 10853-10858

[156] Hotta Y, Nakamura H, Konishi M et al Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology, 2009, 150: 4625-4633

[157] Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology, 2009, 150: 4931-4940

[158] Inagaki T, Dutchak P, Zhao G et al Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab, 2007, 5: 415-425

[159] Wei W, Dutchak PA, Wang X et al Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci USA, 2012, 109: 3143-3148

[160] Wu S, Levenson A, Kharitonenkov A, de Luca F. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J Biol Chem, 2012, 287: 26060-26067

[161] Kubicky RA, Wu S, Kharitonenkov A, de Luca F. Role of fibroblast growth factor 21 (FGF21) in undernutrition-related attenuation of growth in mice. Endocrinology, 2012, 153: 2287-2295

[162] Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr, 2010, 91: 254S-257S

[163] Owen BM, Bookout AL, Ding X et al FGF21 contributes to neuroendocrine control of female reproduction. Nat Med, 2013, 19: 1153-1156

[164] Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun, 2000, 277: 494-498

[165] Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem, 2003, 278: 37419-37426

[166] Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab, 2006, 291: E38-E49

[167] Yoshiko Y, Wang H, Minamizaki T et al Mineralized tissue cells are a principal source of FGF23. Bone, 2007, 40: 1565-1573

[168] Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab, 1997, 82: 674-681

[169] Bianchine JW, Stambler AA, Harrison HE. Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser, 1971, 7: 287-295

[170] Consortium A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet, 2000, 26: 345-348

[171] Shimada T, Muto T, Urakawa I et al Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology, 2002, 143: 3179-3182

[172] White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int, 2001, 60: 2079-2086

[173] Shimada T, Mizutani S, Muto T et al Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA, 2001, 98: 6500-6505

[174] Riminucci M, Collins MT, Fedarko NS et al FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest, 2003, 112: 683-692

[175] Lyles KW, Halsey DL, Friedman NE, Lobaugh B. Correlations of serum concentrations of 1,25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis. J Clin Endocrinol Metab, 1988, 67: 88-92

[176] Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet, 2005, 14: 385-390

[177] Araya K, Fukumoto S, Backenroth R et al A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab, 2005, 90: 5523-5527

[178] Larsson T, Yu X, Davis SI et al A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab, 2005, 90: 2424-2427

[179] Shimada T, Urakawa I, Yamazaki Y et al FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun, 2004, 314: 409-414

[180] Larsson T, Marsell R, Schipani E et al Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology, 2004, 145: 3087-3094

[181] Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology, 2004, 145: 5269-5279

[182] Beck L, Karaplis AC, Amizuka N, Hewson AS, Ozawa H, Tenenhouse HS. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci USA, 1998, 95: 5372-5377

[183] Shimada T, Hasegawa H, Yamazaki Y et al FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res, 2004, 19: 429-435

[184] Shimada T, Kakitani M, Yamazaki Y et al Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Inves, 2004, 113: 561-568

[185] Razzaque MS, Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med, 2006, 12: 298-305

[186] Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab, 2011, 96: 3541-3549

[187] Durham BH, Joseph F, Bailey LM, Fraser WD. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem, 2007, 44: 463-466

[188] Clinkenbeard EL, Farrow EG, Summers LJ et al Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res, 2014, 29: 361-369

[189] Farrow EG, Yu X, Summers LJ et al Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA, 2011, 108: E1146-E1155

[190] Yamazaki Y, Okazaki R, Shibata M et al Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab, 2002, 87: 4957-4960

[191] Fukumoto S, Yamashita T. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med, 2003, 349: 505-506; author reply 505–506

[192] Strom TM, Francis F, Lorenz B et al Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet, 1997, 6: 165-171

[193] Sitara D, Razzaque MS, Hesse M et al Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol, 2004, 23: 421-432

[194] Owen C, Chen F, Flenniken AM et al A novel Phex mutation in a new mouse model of hypophosphatemic rickets. J Cell Biochem, 2012, 113: 2432-2441

[195] Martin A, Liu S, David V et al Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J, 2011, 25: 2551-2562

[196] Feng JQ, Ward LM, Liu S et al Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet, 2006, 38: 1310-1315

[197] Lorenz-Depiereux B, Bastepe M, Benet-Pages A et al DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet, 2006, 38: 1248-1250

[198] Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int, 2003, 64: 2272-2279

[199] Stubbs JR, He N, Idiculla A et al Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res, 2012, 27: 38-46

[200] Quarles LD. The bone and beyond: ‘Dem bones’ are made for more than walking. Nat Med, 2011, 17: 428-430

[201] Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis, 2009, 207: 546-551

[202] Gutierrez OM, Januzzi JL, Isakova T et al Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation, 2009, 119: 2545-2552

[203] Faul C, Amaral AP, Oskouei B et al FGF23 induces left ventricular hypertrophy. J Clin Invest, 2011, 121: 4393-4408

[204] Bhattacharyya N, Chong WH, Gafni RI, Collins MT. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab, 2012, 23: 610-618

[205] Mansour SL, Goddard JM, Capecchi MR. Mice homozygous for a targeted disruption of the proto-oncogene int-2 have developmental defects in the tail and inner ear. Development, 1993, 117: 13-28

[206] Miller DL, Ortega S, Bashayan O, Basch R, Basilico C. Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol, 2000, 20: 2260-2268

[207] Hebert JM, Rosenquist T, Gotz J, Martin GR. FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations. Cell, 1994, 78: 1017-1025

[208] Fiore F, Planche J, Gibier P, Sebille A, deLapeyriere O, Birnbaum D. Apparent normal phenotype of Fgf6 ^−/− mice. Int J Dev Biol, 1997, 41: 639-642

[209] Guo L, Degenstein L, Fuchs E. Keratinocyte growth factor is required for hair development but not for wound healing. Genes Dev, 1996, 10: 165-175

[210] Xu J, Liu Z, Ornitz DM. Temporal and spatial gradients of Fgf8 and Fgf17 regulate proliferation and differentiation of midline cerebellar structures. Development, 2000, 127: 1833-1843

[211] Scearce-Levie K, Roberson ED, Gerstein H et al Abnormal social behaviors in mice lacking Fgf17. Genes Brain Behav, 2008, 7: 344-354

[212] Terauchi A, Johnson-Venkatesh EM, Toth AB, Javed D, Sutton MA, Umemori H. Distinct FGFs promote differentiation of excitatory and inhibitory synapses. Nature, 2010, 465: 783-787

[213] Goldfarb M, Schoorlemmer J, Williams A et al Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. Neuron, 2007, 55: 449-463

[214] Wu QF, Yang L, Li S et al Fibroblast growth factor 13 is a microtubule-stabilizing protein regulating neuronal polarization and migration. Cell, 2012, 149: 1549-1564

[215] Wang Q, Bardgett ME, Wong M et al Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Neuron, 2002, 35: 25-38

[216] Inagaki T, Choi M, Moschetta A et al Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab, 2005, 2: 217-225

[217] Hotta Y, Sasaki S, Konishi M et al Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Dev Dyn, 2008, 237: 2947-2954

[218] Barak H, Huh SH, Chen S et al FGF9 and FGF20 maintain the stemness of nephron progenitors in mice and man. Dev Cell, 2012, 22: 1191-1207

[219] Velocigene. Alleles produced for the KOMP project by Velocigene (Regeneron Pharmaceuticals). MGI Direct Data Submission 2008.

[220] Neve A, Corrado A, Cantatore FP. Osteocytes: central conductors of bone biology in normal and pathological conditions. Acta Physiol, 2012, 204: 317-330

[221] Galli C, Passeri G, Macaluso GM. Osteocytes and WNT: the mechanical control of bone formation. J Dent Res, 2010, 89: 331-343

[222] Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature, 2012, 481: 314-320

[223] Karsenty G. Bone endocrine regulation of energy metabolism and male reproduction. C R Biol, 2011, 334: 720-724

[224] Zhang J, Niu C, Ye L et al Identification of the haematopoietic stem cell niche and control of the niche size. Nature, 2003, 425: 836-841

[225] Sardiwal S, Magnusson P, Goldsmith DJ, Lamb EJ. Bone alkaline phosphatase in CKD-mineral bone disorder. Am J Kidney Dis, 2013, 62: 810-822

[226] Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev, 2005, 208: 207-227

[227] Mundy GR. Osteoporosis and inflammation. Nutr Rev, 2007, 65: S147-S151

[228] Ciruna BG, Schwartz L, Harpal K, Yamaguchi TP, Rossant J. Chimeric analysis of fibroblast growth factor receptor-1 (Fgfr1) function: a role for FGFR1 in morphogenetic movement through the primitive streak. Development, 1997, 124: 2829-2841

[229] Xu X, Qiao W, Li C, Deng CX. Generation of Fgfr1 conditional knockout mice. Genesis, 2002, 32: 85-86

[230] Pirvola U, Ylikoski J, Trokovic R, Hebert JM, McConnell SK, Partanen J. FGFR1 is required for the development of the auditory sensory epithelium. Neuron, 2002, 35: 671-680

[231] Rousseau B, Dubayle D, Sennlaub F et al Neural and angiogenic defects in eyes of transgenic mice expressing a dominant-negative FGF receptor in the pigmented cells. Exp Eye Res, 2000, 71: 395-404

[232] Hajihosseini MK, Lalioti MD, Arthaud S et al Skeletal development is regulated by fibroblast growth factor receptor 1 signalling dynamics. Development, 2004, 131: 325-335

[233] Revest JM, Spencer-Dene B, Kerr K et al Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or Bmp4. Dev Biol, 2001, 231: 47-62

[234] de Moerlooze L, Spencer-Dene B, Revest JM, Hajihosseini M, Rosewell I, Dickson C. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal–epithelial signalling during mouse organogenesis. Development, 2000, 127: 483-492

[235] Hajihosseini MK, Wilson S, de Moerlooze L, Dickson C. A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes. Proc Natl Acad Sci USA, 2001, 98: 3855-3860

[236] Mai S, Wei K, Flenniken A et al The missense mutation W290R in Fgfr2 causes developmental defects from aberrant IIIb and IIIc signaling. Dev Dyn, 2010, 239: 1888-1900

[237] Valverde-Franco G, Binette JS, Li W et al Defects in articular cartilage metabolism and early arthritis in fibroblast growth factor receptor 3 deficient mice. Hum Mol Genet, 2006, 15: 1783-1792

[238] Eswarakumar VP, Schlessinger J. Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3. Proc Natl Acad Sci USA, 2007, 104: 3937-3942

[239] Su N, Xu X, Li C et al Generation of Fgfr3 conditional knockout mice. Int J Biol, 2010, 6: 327-332

[240] Twigg SR, Healy C, Babbs C et al Skeletal analysis of the Fgfr3(P244R) mouse, a genetic model for the Muenke craniosynostosis syndrome. Dev Dyn, 2009, 238: 331-342

[241] Pannier S, Couloigner V, Messaddeq N et al Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia. Biochim Biophys Acta, 2009, 1792: 140-147

[242] Iwata T, Li CL, Deng CX, Francomano CA. Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. Hum Mol Genet, 2001, 10: 1255-1264

[243] Segev O, Chumakov I, Nevo Z et al Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice. Hum Mol Genet, 2000, 9: 249-258

[244] Seitzer N, Mayr T, Streit S, Ullrich A. A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res, 2010, 70: 802-812

[245] Dono R, Texido G, Dussel R, Ehmke H, Zeller R. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J, 1998, 17: 4213-4225

[246] Garmy-Susini B, Delmas E, Gourdy P et al Role of fibroblast growth factor-2 isoforms in the effect of estradiol on endothelial cell migration and proliferation. Circ Res, 2004, 94: 1301-1309

[247] Azhar M, Yin M, Zhou M et al Gene targeted ablation of high molecular weight fibroblast growth factor-2. Dev Dyn, 2009, 238: 351-357

[248] Alvarez Y, Alonso MT, Vendrell V et al Requirements for FGF3 and FGF10 during inner ear formation. Development, 2003, 130: 6329-6338

[249] Holzenberger M, Lenzner C, Leneuve P et al Cre-mediated germline mosaicism: a method allowing rapid generation of several alleles of a target gene. Nucleic Acids Res, 2000, 28: E92

[250] Hatch EP, Noyes CA, Wang X, Wright TJ, Mansour SL. Fgf3 is required for dorsal patterning and morphogenesis of the inner ear epithelium. Development, 2007, 134: 3615-3625

[251] Urness LD, Paxton CN, Wang X, Schoenwolf GC, Mansour SL. FGF signaling regulates otic placode induction and refinement by controlling both ectodermal target genes and hindbrain Wnt8a. Dev Biol, 2010, 340: 595-604

[252] Carlton MB, Colledge WH, Evans MJ. Crouzon-like craniofacial dysmorphology in the mouse is caused by an insertional mutation at the Fgf3/Fgf4 locus. Dev Dyn, 1998, 212: 242-249

[253] Pirvola U, Zhang X, Mantela J, Ornitz DM, Ylikoski J. Fgf9 signaling regulates inner ear morphogenesis through epithelial-mesenchymal interactions. Dev Biol, 2004, 273: 350-360

[254] Behr B, Leucht P, Longaker MT, Quarto N. Fgf-9 is required for angiogenesis and osteogenesis in long bone repair. Proc Natl Acad Sci USA, 2010, 107: 11853-11858

[255] Murakami H, Okawa A, Yoshida H, Nishikawa S, Moriya H, Koseki H. Elbow knee synostosis (Eks): a new mutation on mouse Chromosome 14. Mamm Genome, 2002, 13: 341-344

[256] Puk O, Moller G, Geerlof A et al The pathologic effect of a novel neomorphic Fgf9(Y162C) allele is restricted to decreased vision and retarded lens growth. PLoS ONE, 2011, 6: e23678

[257] Usui H, Shibayama M, Ohbayashi N, Konishi M, Takada S, Itoh N. Fgf18 is required for embryonic lung alveolar development. Biochem Biophys Res Commun, 2004, 322: 887-892

[258] Longaker MT, Behr B, Sorkin M, Manu A, Lehnhardt M, Quarto N. Fgf-18 is required for osteogenesis but not angiogenesis during long bone repair. Tissue Eng Part A, 2011, 17: 2061-2069

[259] Kimura-Ueki M, Oda Y, Oki J et al Hair cycle resting phase is regulated by cyclic epithelial FGF18 signaling. J Invest Dermatol, 2012, 132: 1338-1345

[260] Kharitonenkov A, Shiyanova TL, Koester A et al FGF-21 as a novel metabolic regulator. J Clin Invest, 2005, 115: 1627-1635

[261] Jarosz M, Robbez-Masson L, Chioni AM, Cross B, Rosewell I, Grose R. Fibroblast growth factor 22 is not essential for skin development and repair but plays a role in tumorigenesis. PLoS ONE, 2012, 7: e39436

[262] Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev, 2005, 16: 139-149

[263] Raimann A, Ertl DA, Helmreich M, Sagmeister S, Egerbacher M, Haeusler G. Fibroblast growth factor 23 and Klotho are present in the growth plate. Connect Tissue Res, 2013, 54: 108-117